Sort
48,018 grants matching “immunotherapy”
Immune Impact on Cancer Chemoresistance
$595,421Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2019 · CA
The Impact of FUS-Mediated Brain Cancer Therapy on BBB Transport, Cytokines, and Immunocyte Trafficking
$595,395Kim Butts Pauly · Stanford University · R01 · FY2021 · CA
Analysis of urine tumor nucleic acids for detection and personalized surveillance of bladder cancer
$595,388Maximilian Diehn · Stanford University · R01 · FY2022 · CA
Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation
$595,374Dmitriy Zamarin · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
Career Development in Pediatric and Medical Oncology
$595,080Irwin Bernstein · Fred Hutchinson Cancer Research Center · K12 · FY2009 · CA
Predictive and Diagnostic Radiomic Signatures in Non-Small Cell Lung Cancer (NSCLC) on Immunotherapy
$594,981Despina Kontos · University Of Pennsylvania · R01 · FY2022 · CA
Dissecting the tumor-intrinsic and -extrinsic roles of TBK1 in tumor immunity
$594,912Russell William Jenkins · Massachusetts General Hospital · R37 · FY2024 · CA
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients
$594,873Sacha Gnjatic · Icahn School Of Medicine At Mount Sinai · U01 · FY2020 · DK
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1
$594,846Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U01 · FY2022 · AI
PD-1 modulation of SIV specific CD4 and CD8 T cell responses
$594,813Francois J Villinger · Emory University · R01 · FY2011 · AI
Molecular Imaging of Novel Immuno-therapy and Targeted Therapies for Malignant...
$594,718Antoni Ribas · University Of California Los Angeles · P50 · FY2012 · CA
Genetically-engineered Bacteria Overcome Therapy Resistance
$594,699Ralph R Weichselbaum · University Of Chicago · R01 · FY2025 · CA
Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment
$594,675Waldemar Debinski · Wake Forest University Health Sciences · R01 · FY2023 · CA
Reorienting the Glioblastoma Microenvironment to Respond to Immunotherapy
$594,636Mary Helen Barcellos-Hoff · University Of California, San Francisco · R01 · FY2019 · NS
Advanced Imaging Tools to Assess Cancer Therapeutics in Pediatric
$594,462Heike Elizabeth Daldrup-Link · Stanford University · R01 · FY2024 · CA
ATP1B3: novel regulator of T cell-mediated immunity
$594,452Stefan Feske · New York University School Of Medicine · R01 · FY2024 · AI
Cancer Therapeutics through Theory and Experiment: From Cell Lines to Canine Tumors Grown on the Back of Mice
$594,408Aniruddha Datta · Texas A&M Engineering Experiment Station · · FY2019 · ENG
Rational targeting of Cdc42 to benefit immunotherapy
$594,402Yi Zheng · Cincinnati Childrens Hosp Med Ctr · R01 · FY2025 · CA
Rational targeting of Cdc42 to benefit immunotherapy
$594,402Yi Zheng · Cincinnati Childrens Hosp Med Ctr · R01 · FY2024 · CA
Reprogram long-lived effector T cells for cancer immunotherapy
$594,393Hongbo Chi · St. Jude Children'S Research Hospital · R01 · FY2021 · CA
Reprogram long-lived effector T cells for cancer immunotherapy
$594,393Hongbo Chi · St. Jude Children'S Research Hospital · R01 · FY2020 · CA
Transcriptional Reprogramming in Melanoma Plasticity
$594,386Chengyu Liang · Wistar Institute · R01 · FY2025 · CA
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy
$594,336Zihai Li · Ohio State University · R01 · FY2022 · CA
Ablating Liver Metastases with SBRT to Enhance Immune Checkpoint Blockade in Melanoma
$594,335Michael Daniel Green · University Of Michigan At Ann Arbor · R01 · FY2023 · CA
Defining the T-cell Response to Human Renal Cancer
$594,220James C Yang · Division Of Clinical Sciences - Nci · Z01 · FY2008 · CA